WaveMan
WaveMan · Company
VVOS · Vivos Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VVOS Vivos Therapeutics (VVOS) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001716166
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter

What the filings say about VVOS

Activist stakes (13D), 180 days
1 filing
Largest: 19.9% of the class

Vivos Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Vivos Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
V-Co Investors 3 LLC
BUY
2026-04-02 SECtraded 2026-03-31
308,848
$413.9K
-90.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 22.8% of the 1,353,625 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider V-Co Investors 3 LLC bought about $413.9K of VVOS on Mar 31, 2026, the largest insider purchase at the company on our record; 5 funds added in the latest 13F quarter.
V-Co Investors 3 LLC
BUY
2026-04-02 SECtraded 2026-03-31
1,044,777
$1.4M
-90.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,044,777 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider V-Co Investors 3 LLC bought about $1.4M of VVOS on Mar 31, 2026, the largest insider purchase at the company on our record; 5 funds added in the latest 13F quarter.
Huntsman Ronald Kirk
Chief Executive Officer
BUY
2023-06-20 SEC
14,000
$7.4K
-99.0%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jun 16, 2023.
  • -39.4% median (-34.3% mean) 90-day return after 8 previous buys.
  • The trade is 16.2% of the 86,521 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Huntsman Ronald Kirk bought about $7.4K of VVOS on Jun 20, 2023; 5 funds added in the latest 13F quarter.
Huntsman Ronald Kirk
Chief Executive Officer
BUY
2023-06-20 SECtraded 2023-06-16
5,000
$2.6K
-99.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jun 15, 2023.
  • -38.4% median (-31.9% mean) 90-day return after 7 previous buys.
  • The trade is 6.9% of the 72,521 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Huntsman Ronald Kirk bought about $2.6K of VVOS on Jun 16, 2023; 5 funds added in the latest 13F quarter.
Huntsman Ronald Kirk
Chief Executive Officer
BUY
2023-06-20 SECtraded 2023-06-16
10,000
$5.4K
-99.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jun 15, 2023.
  • -38.4% median (-31.9% mean) 90-day return after 7 previous buys.
  • The trade is 14.8% of the 67,521 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Huntsman Ronald Kirk bought about $5.4K of VVOS on Jun 16, 2023; 5 funds added in the latest 13F quarter.
12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 7 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 97% of Medical Devices
Revenue
+16.0% year over year
more than 64% of Medical Devices
Margin
-121.4% net margin
below 81% of Medical Devices
Buybacks
no share repurchases reported
Short interest
15.0% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 95% of Medical Devices
The situation: each line is one rule over one dataset
V-CO Investors LLC disclosed a 5%+ stake (3.7%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch VVOS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-95.7%12M
-96%-63%-31%+1%2025-102025-122026-022026-042026-062026-082026-10 2026-03-31 · V-Co Investors 3 LLC bought $1.4M2026-03-31 · V-Co Investors 3 LLC bought $413.9K2026-07-15 · V-CO Investors LLC filed a 5%+ stake (3.7%)2026-07-15 · V-Co Investors 2 LLC filed a 5%+ stake (5.9%)2026-07-15 · V-Co Investors 3 LLC filed a 5%+ stake (9.7%)2026-07-15 · V-Co Investors 4 LLC filed a 5%+ stake (0.6%)2026-07-15 · SP Manager LLC filed a 5%+ stake (19.9%)2026-07-15 · Michael C. Skaff filed a 5%+ stake (19.9%)2026-04-02 · V-CO Investors LLC filed a 5%+ stake (3.8%)2026-04-02 · V-Co Investors 2 LLC filed a 5%+ stake (6.1%)2026-04-02 · V-Co Investors 3 LLC filed a 5%+ stake (10.0%)2026-04-02 · SP Manager LLC filed a 5%+ stake (19.9%)2026-04-02 · Michael C. Skaff filed a 5%+ stake (19.9%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VVOS: institutional holders (13F)

13F holdings, latest reported quarter
GEODE CAPITAL MANAGEMENT, LLC
85,001 sh
$38.6K
IHT Wealth Management, LLC
76,736 sh
$34.9K
VANGUARD CAPITAL MANAGEMENT LLC
60,629 sh
$27.6K
COMMONWEALTH EQUITY SERVICES, LLC
42,500 sh
$19.3K
B. Riley Wealth Advisors, Inc.
38,066 sh
$18.8K

Congress trades in VVOS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
V-CO Investors LLC
Activist 13D · 2026-07-15
3.7%
V-Co Investors 2 LLC
Activist 13D · 2026-07-15
5.9%
V-Co Investors 3 LLC
Activist 13D · 2026-07-15
9.7%
V-Co Investors 4 LLC
Activist 13D · 2026-07-15
0.6%
SP Manager LLC
Activist 13D · 2026-07-15
19.9%

VVOS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

VVOS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$42.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$27.6K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$8.5K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$5.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

VVOS financials

Revenue growth
+16.0%
XBRL, annual
Net margin
-121.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$20.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-122.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$19.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-2.11x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-6,645%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-101.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-193.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$8.9M
market value at close 2026-10-27 on 2026-08-13 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-738.3%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$17.4M$15.0M$13.8M$16.0M
Gross profit$10.5M$9.0M$8.3M$10.0M
Operating income-$19.9M-$11.2M-$17.3M-$25.0M
Net income-$21.2M-$11.1M-$13.6M-$23.8M
EPS (diluted)-2.07-2.22-11.14-25.90
Operating cash flow-$15.3M-$12.7M-$11.9M-$19.6M
Cash$2.0M$6.3M$1.6M$3.5M
Long-term debt$469.0K$1.2M$1.2Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

VVOS Stock Sonar score 5/7 axes

Find similar shapesCompare

VVOS ranks highest on growth (64th percentile) and financial health (22nd), and lowest on profitability (9th), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
9
Inputs
  • Return on equity-6645% · 0 pct, sector of 183
  • Return on assets-101.7% · 17 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-193.1% · 9 pct, sector of 188
Financial health
22
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-2.11x · 22 pct, sector of 150
Growth
64
Inputs
  • Revenue growth, YoY+16.0% · 64 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
17
Inputs
  • Funds adding, latest quarter5 · 3 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$130K · 31 pct, sector of 50
Risk and compliance
10
Inputs
  • Short interest, % of float+15.0% · 8 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+23.1% · 12 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VVOS filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 19.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies